Stock Analiz

Cellyan Biotechnology Co., Ltd HKPD

Other Pharmaceuticals · IPO 2025 · data as of November 13, 2026

$1.62Market cap $4M
Open the interactive analysis →

Cellyan Biotechnology Co., Ltd (HKPD) is a healthcare company listed in the US with a market value of about $4M. In fiscal year 2026 it had revenue of $13M and net income of -$1M, a net margin of -8.5%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -119%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.

About Cellyan Biotechnology Co.

Cellyan Biotechnology Co. is listed in the US and classified in other pharmaceuticals, IPO year 2025. Revenue went from $13M in 2023 to $13M in 2026, growth of about 2.3% a year. It was profitable in 2 of the last 4 years in our data. Its share count fell by 67% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-19.9%
Shareholder yield0.0%
Intrinsic value vs. price−81%

Growth and quality

Revenue growth (1 yr)21.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)5.3%
ROIC (5-yr avg.)-118.8%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 4 years

Fiscal year2026202520242023
Revenue$13M$20M$17M$13M
Net income-$1M-$27056$1M$998196
Free cash flow-$794145$499298-$447066$2M
EPS (diluted)$-0.46$-0.00$0.18$0.13
Net margin-8.5%-0.1%8.0%8.0%
ROIC—-26.3%-30.7%-299.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Cellyan Biotechnology Co. stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cellyan Biotechnology Co. pay a dividend?

Not currently.

Is Cellyan Biotechnology Co. a good stock to buy?

We do not give buy or sell advice. Cellyan Biotechnology Co. scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.